Matthew Harrison

In a report published Wednesday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Amgen, Inc. (NASDAQ: AMGN), but removed the $143.00 price target. In the report, Morgan Stanley noted, “Amgen is developing brodalumab together with AstraZeneca. We currently model Amgen...

In a report published Thursday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Pharmacyclics, Inc. (NASDAQ: PCYC), but removed the $101.00 price target. In the report, Morgan Stanley noted, “This morning the Veterans Affairs National Acquisition Center posted a...

In a report published Thursday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Amgen, Inc. (NASDAQ: AMGN), but removed the $143.00 price target. In the report, Morgan Stanley noted, “We highlight key takeaways from Amgen's presentation at our Healthcare Conference. "High...

In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Regeneron Pharmaceuticals (NASDAQ: REGN), but removed the $310.00 price target. In the report, Morgan Stanley noted, “We believe positive data is already priced into REGN and expect minimal...

In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Biogen Idec (NASDAQ: BIIB), but removed the $395.00 price target. In the report, Morgan Stanley noted, “Friday's approval was in-line with expectations following a 3 month PDUFA date extension....

In a report published Wednesday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Celgene (NASDAQ: CELG), but removed the $75.00 price target. In the report, Morgan Stanley noted, “Risks to EU patents may be underappreciated by consensus as Revlimid could go generic as...

In a report published Thursday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Regeneron Pharmaceuticals (NASDAQ: REGN), but removed the $310.00 price target. In the report, Morgan Stanley noted, “Dupilumab (IL-4R antibody) achieved statistical significant reductions...

In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Gilead Sciences (NASDAQ: GILD), but removed the $75.00 price target. In the report, Morgan Stanley noted, “While we acknowledge that the bull case of emerging market (EM) revenues backstopping...

In a report published Wednesday, Morgan Stanley analyst Matthew Harrison initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI) with an Overweight rating and $17.00 price target. In the report, Morgan Stanley noted, “Differentiated data in iNHL represents a viable path to market for Infinity...

Citing “no upside driver beyond Kadcyla,” Morgan Stanley initiated coverage on ImmunoGen (NASDAQ: IMGN) with an Underweight rating and $10 price target (22.2 percent downside). In the best case scenario, Morgan Stanley analyst Matthew Harrison sees Kadcyla capturing 50 percent of...

In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Celgene (NASDAQ: CELG), but removed the $150.00 price target. In the report, Morgan Stanley noted, “Agios' AG-221 is a targeted therapy for AML (IDH2m or ~15% of all AML) which Celgene...

In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Amgen (NASDAQ: AMGN), but removed the $140.00 price target. In the report, Morgan Stanley noted, “David W. Meline, former CFO of 3M, appointed new CFO: Meline joins from 3M where he served as...

In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Biogen Idec (NASDAQ: BIIB), but removed the $395.00 price target. In the report, Morgan Stanley noted, “RPC1063 is an oral S1P1 receptor modulator (same as Novartis' Gilenya) which could...

In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Biogen Idec (NASDAQ: BIIB), but removed the $395.00 price target. In the report, Morgan Stanley noted, “Eloctate is the second product in Biogen's hemophilia franchise to be approved (Alprolix...

In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Pharmacyclics (NASDAQ: PCYC), but removed the $100.00 price target. In the report, Morgan Stanley noted, “Mgt hosted an investor event. Three KOLs from the RESONATE study responded to mgt....